Genomic Location of PRMT6-Dependent H3R2 Methylation Is Linked to the Transcriptional Outcome of Associated Genes by Bouchard, C. (Caroline) et al.
ArticleGenomic Location of PRMT6-Dependent H3R2
Methylation Is Linked to the Transcriptional
Outcome of Associated GenesGraphical AbstractHighlightsd PRMT6 deposits H3R2me2a at promoters as well as
enhancers of active genes
d H3R2me2a influences the occurrence of adjacent histone
marks (H3K4me3, H3K4me1, H3K27ac)
d H3R2me2a contributes to gene repression at promoters and
gene activation at enhancers
d PRMT6/H3R2me2a modulate the transcription of important
neural differentiation genesBouchard et al., 2018, Cell Reports 24, 3339–3352
September 18, 2018 ª 2018 The Author(s).
https://doi.org/10.1016/j.celrep.2018.08.052Authors
Caroline Bouchard, Peeyush Sahu,
Marion Meixner, ..., Thorsten Stiewe,
Sjaak Philipsen, Uta-Maria Bauer
Correspondence
bauer@imt.uni-marburg.de
In Brief
Bouchard et al. identify the genome-wide,
PRMT6-dependent occurrence of
H3R2me2a in a cell model of neural
differentiation. H3R2me2a is localized at
promoters and enhancers of active genes
and influences the chromatin recruitment
of histone lysine methyltransferases.
Thereby, H3R2me2a modulates the
deposition of adjacent histone H3 marks
and regulates the transcriptional output
of genes relevant for pluripotency and
differentiation.Data and Software AvailabilityGSE107612
Cell Reports
ArticleGenomic Location of PRMT6-Dependent
H3R2 Methylation Is Linked
to the Transcriptional Outcome of Associated Genes
Caroline Bouchard,1,12 Peeyush Sahu,1,12 Marion Meixner,1,12 Rene´ Reiner No¨tzold,1,12 Marco B. Rust,2
Elisabeth Kremmer,3 Regina Feederle,4 Gene Hart-Smith,5 Florian Finkernagel,6 Marek Bartkuhn,7
Soni Savai Pullamsetti,8 Andrea Nist,9 Thorsten Stiewe,9,10 Sjaak Philipsen,11 and Uta-Maria Bauer1,13,*
1Institute for Molecular Biology and Tumor Research (IMT), Philipps-University Marburg, Hans-Meerwein-Strasse 2, BMFZ, 35043 Marburg,
Germany
2Molecular Neurobiology Group, Institute of Physiological Chemistry, Philipps-University Marburg, Karl-von-Frisch-Strasse 1,
35043 Marburg, Germany
3Institute of Molecular Immunology, Helmholtz ZentrumM€unchen, German Research Center for Environmental Health GmbH, 81377Munich,
Germany
4Monoclonal Antibody Core Facility, Institute for Diabetes and Obesity, Helmholtz Zentrum M€unchen, German Research Center for
Environmental Health GmbH, Ingolsta¨dter Landstrasse 1, 85764 Neuherberg, Germany
5School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, New South Wales 2052, Australia
6Center for Tumor Biology and Immunology (ZTI), Philipps-University Marburg, Hans-Meerwein-Strasse 3, 35043 Marburg, Germany
7Institute for Genetics, Justus-Liebig-University Giessen, Heinrich-Buff-Ring 58-62, 35392 Giessen, Germany
8Department of Lung Development and Remodeling, Max-Planck-Institute for Heart and Lung Research, Member of the German Center for
Lung Research (DZL), Bad Nauheim, Germany
9Genomics Core Facility, Philipps-University Marburg, Hans-Meerwein-Strasse 3, 35043 Marburg, Germany
10Institute of Molecular Oncology, Philipps-University Marburg, Hans-Meerwein-Strasse 3, 35043 Marburg, Germany
11Department of Cell Biology, Erasmus MC, Rotterdam, the Netherlands
12These authors contributed equally
13Lead Contact
*Correspondence: bauer@imt.uni-marburg.de
https://doi.org/10.1016/j.celrep.2018.08.052SUMMARY
Protein arginine methyltransferase 6 (PRMT6) cata-
lyzes asymmetric dimethylation of histone H3 at argi-
nine 2 (H3R2me2a). This mark has been reported to
associate with silent genes. Here, we use a cell
model of neural differentiation, which upon PRMT6
knockout exhibits proliferation and differentiation
defects. Strikingly, we detect PRMT6-dependent
H3R2me2a at active genes, both at promoter and
enhancer sites. Loss of H3R2me2a from promoter
sites leads to enhanced KMT2A binding and
H3K4me3 deposition together with increased target
gene transcription, supporting a repressive nature
of H3R2me2a. At enhancers, H3R2me2a peaks co-
localize with the active enhancer marks H3K4me1
and H3K27ac. Here, loss of H3R2me2a results in
reduced KMT2D binding and H3K4me1/H3K27ac
deposition together with decreased transcription of
associated genes, indicating that H3R2me2a also ex-
erts activation functions. Our work suggests that
PRMT6 via H3R2me2a interferes with the deposition
of adjacent histone marks and modulates the activity
of important differentiation-associated genes by
opposing transcriptional effects.Cell Report
This is an open access article under the CC BY-NINTRODUCTION
A multitude of nuclear and cytoplasmic proteins are posttransla-
tionally modified by arginine methylation. Arginines frequently
contribute to intermolecular interactions due to hydrogen-
bonding and amino-aromatic interactions. Methylation of such
pivotal arginine residues modulates the binding affinity between
interaction partners leading to promotion or inhibition of interac-
tions (Gayatri and Bedford, 2014). The enzymes responsible for
this modification are protein arginine methyltransferases
(PRMTs), which constitute an enzyme family of nine members
in mammals (Yang and Bedford, 2013). They transfer methyl
groups from the ubiquitous methyl-group donor S-adenosyl-L-
methionine (SAM) to the terminal guanidino nitrogens of arginine
residues, giving rise to monomethyl-arginine (MMA), asymmetric
dimethyl-arginine (ADMA), or symmetric dimethyl-arginine
(SDMA). PRMTs regulate a wide range of essential cellular pro-
cesses, for example, signal transduction, nucleo-cytoplasmic
transport, transcriptional regulation, RNA splicing, and DNA
repair (Yang and Bedford, 2013).
Our previous studies identified asymmetric dimethylation of
histone H3 at arginine 2 (H3R2me2a) as the predominant histone
mark catalyzed by the family member PRMT6 (Hyllus et al.,
2007). H3R2me2a was found to contribute to gene repression
by blocking the catalytic activity of the H3K4 methyltransferase
KMT2A and counteracting the formation of H3K4 trimethylation
(Guccione et al., 2007; Hyllus et al., 2007; Iberg et al., 2008;s 24, 3339–3352, September 18, 2018 ª 2018 The Author(s). 3339
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Kirmizis et al., 2007; Michaud-Levesque and Richard, 2009;
Stein et al., 2012). In agreement with these observations,
H3R2me2a was shown to be depleted from active genes and
present at genomic regions with low H3K4me3 occupancy,
such as silent genes and heterochromatin (Barski et al., 2007;
Rosenfeld et al., 2009). Transcriptional repression by PRMT6
and H3R2me2a was reported to be relevant for pluripotency, dif-
ferentiation processes, as well as maintenance of fully differenti-
ated cells in various tissues (Dhawan et al., 2011; Lee et al., 2012;
Stein et al., 2016). Given that until now our understanding of the
gene-regulatory functions of H3R2me2a derived from analyses
of individual genes and subsets of genomic loci, we investigated
here the PRMT6-dependent transcriptome and genomic distri-
bution of H3R2me2a in an unbiased and genome-wide manner.
Moreover, we studied the putative cross talk between
H3R2me2a and neighboring histone marks, such as H3K4
methylation (H3K4me1 and H3K4me3), H3K27 methylation
(H3K27me3), and H3K27 acetylation (H3K27ac).
For these studies, we used the human embryonal carcinoma
cell line NT2/D1, which is pluripotent and differentiates into neu-
ral precursor cells upon treatment with all-trans retinoic acid
(ATRA) (Lee and Andrews, 1986). We chose this model since
PRMT6 knockdown causes alterations in the transcriptional pro-
gram of undifferentiated as well as ATRA-induced NT2/D1 cells
(Hyllus et al., 2007; Stein et al., 2016). PRMT6 wild-type and
knockout NT2/D1 cells were employed in chromatin immunopre-
cipitation-sequencing (ChIP-seq) and RNA-sequencing (RNA-
seq) analyses. In contrast to our expectations, we found that
H3R2me2a is deposited in a PRMT6-dependent manner primar-
ily at active genes, both at promoter and enhancer sites. Here,
H3R2me2a seems to contribute to the transcriptional regulation
of important pluripotency and differentiation-associated genes
by influencing the deposition of neighboring histone marks.
Our data support the concept that arginine methylation exerts
its regulatory activity by modulating protein-protein interactions.
Depending on its genomic location, H3R2me2a possesses either
a repressive or activating nature: transcriptional repression at
promoters and transcriptional activation at enhancers.
RESULTS
PRMT6-Dependent H3R2me2a Is Predominantly
Deposited at TSS and Promoter Regions in
Undifferentiated NT2/D1 Cells
By combining genome-wide analyses on the H3R2me2a deposi-
tion profile (ChIP-seq) and the PRMT6-dependent transcriptome
(RNA-seq), we aimed to elucidate the functional andmechanistic
impact of PRMT6 and its major histone mark in gene regulation.
We used CRISPR/Cas9 genome editing to generate PRMT6
knockout (KO) and control (CT) NT2/D1 cells. NT2/D1 KO cell
lines showed a complete loss of PRMT6 expression and a global
reduction of arginine methylated proteins in comparison to CT
cells (Figure 1A). Furthermore, we generated an antibody, which
specifically recognizes the H3R2me2amodification, also in pres-
ence of the neighboring H3K4me3 mark (Figures S1A–S1E).
Monomethylated H3R2 (H3R2me1) was weakly detected by
the antibody, whereas unmethylated H3R2 (H3R2me0), symmet-
rically dimethylated H3R2 (H3R2me2s), and other methylation3340 Cell Reports 24, 3339–3352, September 18, 2018marks of the H3 as well as H4 N terminus were not recognized
(Figures S1A–S1E). We performed ChIP-seq using this antibody
and obtained in undifferentiated NT2/D1 CT cells a total of 2,300
binding sites, as visualized by heatmap (Figure 1B). In contrast,
ChIP-seq datasets of two NT2/D1 KO cell lines revealed a strong
reduction of H3R2me2a signals indicating that these 2,300 sites
are PRMT6 dependent (Figures 1B and S1F). Analysis of the rela-
tive genomic distribution of the H3R2me2a sites showed that
72% of these occur in the vicinity of transcriptional start sites
(TSSs) (Figure 1C). To validate these ChIP-seq results, we
selected candidate loci, as depicted in the genome browser
views for NT2/D1 CT and KO cells (Figures 1D and S1G). Using
independent ChIP-qPCR assays, we confirmed the H3R2me2a
occupancy at these loci in undifferentiated NT2/D1 CT cells as
well as the loss of H3R2me2a enrichment upon PRMT6 deletion
(Figures 1E and S1H). Control regions in proximity to H3R2me2a
binding sites revealed background signal of H3R2me2a in NT2/
D1 CT and KO cells (Figure 1E). Native ChIP analysis in CT cells
reproduced the H3R2me2a binding sites (Figure S1I). Further-
more, re-expression of PRMT6 in KO cells resulted in the re-
establishment of H3R2me2a occupancy (Figures S2A–S2D).
Hence, these results uncover the genome-wide binding profile
of PRMT6-dependent H3R2me2a in pluripotent NT2/D1 cells.
The predominant TSS and promoter-proximal distribution of
H3R2me2a suggests that this mark is likely involved in the regu-
lation of gene expression.
H3R2me2a Deposition Displays Three Distinct Patterns
during ATRA-Induced NT2/D1 Cell Differentiation
Next, we analyzed the dynamics of H3R2me2a deposition during
NT2/D1 cell differentiation upon ATRA treatment. A total of 8,819
unique H3R2me2a binding sites was detected by ChIP-seq in un-
differentiated and differentiated NT2/D1 CT cells, which encom-
passed the 2,300 peaks of undifferentiated cells and additional
6,519 peaks acquired upon differentiation. Based on their enrich-
ment in the minus-ATRA and plus-ATRA conditions, we divided
thesepeaks into threeclusters (Figure2A). Cluster I peaksarepre-
sent in the minus-ATRA condition and are reduced or lost upon
ATRA treatment, cluster II peaks are equally strong in both
ATRA conditions, and cluster III peaks show a gain of
H3R2me2a enrichment upon ATRA-induced differentiation. In
NT2/D1 KO cells, the peaks of all three clusters were significantly
reduced (Figure 2A). Using geneontology (GO) analysis, we found
that genes associated with the three different peak clusters
execute distinct and essential functions in NT2/D1 cells (Fig-
ure 2B). Cluster I-associated genes were predominantly anno-
tated to terms such as axon guidance, stem cell maintenance,
and pluripotency, as exemplified by the genes OCT4, NANOG,
ID1, andREST, which are downregulated upon neural differentia-
tion (Figure 2B). Cluster II genes, e.g.,ST3GAL2,MITF, FASTKD1,
CNOT1, and LARS, revealed as overrepresented GO terms cell
cycle, RNA processing, chromatin organization, DNA damage
response, and posttranslational modifications (PTMs). These
peaks showed particularly robust enrichment, as validated in Fig-
ure 1E, and associate with genes that are not responsive to ATRA
treatment (Figure 2B). In cluster III, the overrepresentedGO terms
were cell cycle, CNS development, and neurogenesis. Gene
examples are the HOXA cluster, RARB, VTCN1, CRABP1, and
Figure 1. PRMT6-Dependent and Promoter-
Proximal Deposition of H3R2me2a in NT2/D1
Cells
(A) Protein extracts of undifferentiated control (CT)
or PRMT6-deleted (KO-1, KO-2) NT2/D1 cell lines
were analyzed by western blot using the indicated
antibodies (a-PRMT6, a-ADMA, a-CDK2). CDK2
staining served as loading control. Size markers (in
kilodaltons) are shown on the left.
(B) Heatmap displays the H3R2me2a ChIP-seq
signals in undifferentiated NT2/D1 CT cells over the
2,300 binding sites sorted in the descending order
of their signal strength (±3 kb around the centered
summits) in comparison to H3R2me2a ChIP-seq
profiles of NT2/D1 KO-1 and KO-2 cell lines.
(C) Relative distribution of the 2,300 H3R2me2a
peaks (of B) is shown within different genomic re-
gions compared to the distribution of these regions
in the human genome.
(D) Genome browser views of H3R2me2a ChIP-seq
datasets of NT2/D1 CT (two replicates) and both
KO cell lines are shown for five gene loci. Positions
of amplicons (spec, specific region) generated by
qPCR (E) are depicted as black boxes above the
top browser tracks. Data range is indicated in
brackets.
(E) ChIP-qPCR assays were performed in NT2/D1
CT and KO cells (=KO-2, which we employed in
all subsequent experiments as PRMT6 knockout
cell line) using control antibodies (IgG) and
a-H3R2me2a. Precipitated DNA was analyzed by
qPCR with primers amplifying the H3R2me2a
peaks (spec) or a nearby control region (control) of
the depicted loci. Amplicons for control regions are
in case of CNOT1 16 kb downstream of TSS in
intron 1 and in case of LARS 18 kb downstream of
TSS in exon 6. Recruitment is displayed in percent
input of chromatin; mean ± SD of triplicates.ARID1A, which are predominantly upregulated upon ATRA treat-
ment (Figure 2B). In ChIP-qPCR and RT-qPCR assays, we vali-
dated several candidate genes of the three clusters for their
H3R2me2a occupancy and transcriptional characteristics in un-
differentiated and ATRA-treated NT2/D1 CT cells, such as OCT4
and ID1 for cluster I, LARS and MITF for cluster II, and VTCN1
and CRABP1 for cluster III (Figures 2C and S3A). These results
demonstrate that H3R2me2a displays differentiation-dependent
dynamics in NT2/D1 cells andmarks genes, which exert essential
functions in pluripotency, cell cycle, and neural differentiation.
H3R2me2a Co-localizes with Other Histone H3 Marks
and Associates with Active Genes
Given that H3R2me2a has been reported to influence the
occurrence of adjacent histone H3 modifications, in particularCell ReportsH3K4me3 (Guccione et al., 2007; Hyllus
et al., 2007), we analyzed the distribution
of this promoter mark in undifferentiated
and differentiated NT2/D1 CT cells by
ChIP-seq. Surprisingly, we found that
48% (4,236 peaks) of the total 8,819
H3R2me2a sites overlap with a high occu-pancy of H3K4me3 but not with H3K27me3, suggesting that
H3R2me2a is mainly present at non-bivalent, active gene pro-
moters (Figures 2D, S3B, and S3C). No global changes in the
H3K4me3 occupancy were observed when comparing minus/
plus-ATRA conditions. Genes of all three clusters contributed
to this group of promoter-associated H3R2me2a peaks. The re-
maining 4,538 H3R2me2a sites displayed very low occupancy of
H3K4me3 (Figure 2D) and high enrichment of non-TSS regions
(data not shown). This prompted us to examine the distribution
of two enhancer modifications, H3K4me1 and H3K27ac.
H3K4me1 alone marks primed enhancers, whereas H3K4me1
in conjunction with H3K27ac characterizes active enhancers
(Calo and Wysocka, 2013). Interestingly, we observed that the
remaining 52% H3R2me2a binding sites predominantly co-
occur with sites of high H3K4me1 and H3K27ac occupancy,24, 3339–3352, September 18, 2018 3341
Figure 2. Dynamics of the Genome-wide
H3R2me2a Deposition during NT2/D1 Cell
Differentiation and Co-occurrence of
H3R2me2a with Other Histone H3 Marks
(A) Heatmap of H3R2me2a ChIP-seq binding pro-
file (±3 kb around the centered peak summits) in
NT2/D1 CT versus KO cells minus/plus ATRA at
8,819 genomic loci. Peaks are divided into three
clusters (I, II, and III) depending on their H3R2me2a
enrichment in the minus- and plus-ATRA condi-
tions.
(B) Table summarizing the characteristics of genes
associated with H3R2me2a binding sites of the
three clusters. Overrepresented GO terms and their
corresponding q values are indicated.
(C) Genome browser views of the H3R2me2a ChIP-
seq datasets of NT2/D1 CT cells minus/plus ATRA
are depicted for gene loci illustrating the three
clusters (left panels): OCT4 (cluster I), LARS
(cluster II), and VTCN1 (cluster III). Positions of
amplicons generated by qPCR are depicted as
black boxes above the top browser tracks. Data
range is indicated in brackets. ChIP-qPCR assays
were performed using control antibodies (IgG)
and a-H3R2me2a and primers amplifying the
H3R2me2a peaks of the depicted loci. Recruitment
is displayed in percent input of chromatin; mean ±
SD of triplicates (middle panels). Total RNA was
analyzed by RT-qPCR for the transcript levels
derived from three gene loci. Values were normal-
ized toUBIQUITIN (UBC) expression and presented
relative to the minus-ATRA condition; mean ± SD of
triplicates (right panels).
(D) Heatmap displays the H3R2me2a ChIP signals
over 8,819 sites in comparison to ChIP-seq profiles
of histone marks (H3K4me3, H3K4me1, and
H3K27ac) in NT2/D1 CT cells minus/plus ATRA, as
regions classified in promoters (4,236 sites) or en-
hancers (4,583 sites) based on the signal strength
of their specific histone marks.
(E) RNA-seq analysis was performed in NT2/D1 CT
cells plus ATRA. Genes associatedwith H3R2me2a
binding sites either at their promoter or enhancer
were binned according to their transcriptional
strength in four categories based on expression
quantiles (normalized as TPM [transcript per
million reads per kilobase]): low, <0.09 and >0;
medium, <0.84 and R0.09; medium-high, <10.5
andR0.84; high, >10.5.indicating that here H3R2me2a localizes with active enhancer
regions (Figure 2D). These enhancer-associated H3R2me2a
binding sites showed an increase in H3K4me1 and H3K27ac oc-
cupancy concomitant to the gain in H3R2me2a enrichment upon
ATRA treatment. Over 80% of the H3R2me2a enhancer sites
belong to cluster III. To address whether the here-observed
H3R2me2a deposition feature is a cell-type-specific phenome-
non, we performed ChIP-seq analysis of this mark in the human
osteosarcoma cell line U2OS with either wild-type levels of
PRMT6 (CT) or PRMT6 KO. Thereby, we identified 3,253
PRMT6-dependent H3R2me2a sites, of which 47% (1,556
peaks) overlapped with peaks in NT2/D1 cells (Figures S4A–
S4F). Interestingly, as observed in NT2/D1 cells, H3R2me2a3342 Cell Reports 24, 3339–3352, September 18, 2018sites in U2OS cells were co-occupied by H3K4me3 or
H3K4me1/H3K27ac (Figure S4G). Thus, our results indicate
that the co-occurrence of H3R2me2a with these other H3 marks
is a general and cell-type-independent characteristic.
To determine the transcriptional output of genes with either
promoter- or enhancer-deposited H3R2me2a in NT2/D1 cells,
we performed RNA-seq analyses. We then binned all
H3R2me2a-associated unique genes (6,697) according to their
transcription levels in differentiated CT cells. We found that
H3R2me2a at promoters predominantly marks highly tran-
scribed genes, whereas H3R2me2a at enhancers is located in
proximity to genes distributed in all four categories of expression
levels (Figure 2E). Our observations were unexpected, since up
to now PRMT6 and H3R2me2a have been reported to mainly
associate with silent genes (Guccione et al., 2007; Hyllus et al.,
2007; Iberg et al., 2008; Kirmizis et al., 2007). Altogether, these
results reveal that H3R2me2a possesses two distinct locations
in the genome, at promoter and enhancer sites. At both loca-
tions, H3R2me2a co-occurs with active histone modifications
and consistently marks primarily active genes.
H3R2me2a Contributes to Activation as well as
Repression of Associated Genes
To address whether H3R2me2a influences the transcriptional
output of the associated genes, we compared the PRMT6-
dependent transcriptome of NT2/D1 CT and KO cells by RNA-
seq. We identified 710 differentially expressed genes in ATRA-
stimulated cells (Figure S5A). These deregulated genes were
almost equally distributed into the upregulated and downregu-
lated groups, respectively (374 upregulated genes and 336
downregulated genes). To distinguish direct from indirect tran-
scriptional effects of PRMT6-dependent H3R2me2a, we com-
bined our ChIP-seq and RNA-seq datasets. This analysis
showed that approximately 25% of deregulated genes (176
genes) harbor H3R2me2a binding sites in their proximity. A
larger number of genes with enhancer-deposited H3R2me2a
was deregulated compared to genes with promoter-deposited
H3R2me2a (Figure S5B). The majority of these direct
H3R2me2a targets (70%) were downregulated upon PRMT6
knockout, indicating that PRMT6-dependent H3R2me2a pre-
dominantly contributes to transcriptional activation of associ-
ated genes. This effect was more pronounced for genes
associated with H3R2me2a enhancer peaks (Figure S5B). Alto-
gether, our results indicate that H3R2me2a contributes to gene
repression as well as gene activation, the latter accounting for
the majority of effects.
Promoter-Associated H3R2me2a Attenuates H3K4me3
Occupancy and Transcriptional Activity
We next investigated whether promoter-associated H3R2me2a
influences the deposition of H3K4me3 and the transcriptional
output of the associated genes. Thus, we plotted the intensity
of H3K4me3 signals in NT2/D1 CT versus KO cells and found
that the H3K4me3 occupancy of upregulated genes is signifi-
cantly increased upon PRMT6 knockout (Figures 3A and S5C).
On the contrary, the downregulated genes showed no significant
difference in the H3K4me3 deposition between CT and KO cells.
Our findings suggest that PRMT6 and H3R2me2a negatively in-
fluence H3K4me3 deposition at the chromatin. Independent
ChIP-qPCR verified the higher occupancy of H3K4me3 for genes
of all three clusters in PRMT6-deficient cells (Figures 3B and
S5D). Moreover, this increase in H3K4me3 occupancy coincided
with an elevated transcriptional activity (Figures 3C andS5D) and
an enhanced KMT2A binding to theseH3R2me2a target genes in
KO cells (Figure 3D). Our data indicate that promoter-associated
H3R2me2a possesses a repressive nature by interfering with the
recruitment of KMT2A and antagonizing the deposition of
H3K4me3. However, in contrast to previous perceptions (Guc-
cione et al., 2007; Hyllus et al., 2007; Iberg et al., 2008), this
repressive function of H3R2me2a does not occur at silent gene
loci, but rather at active genes, causing a restraint of their tran-scriptional output. Thus, H3R2me2a localized at promoters
leads to fine-tuning of transcriptional activities and impedes un-
authorized high expression of pluripotency genes (cluster I, Fig-
ure 2B) as well as differentiation-associated genes (cluster III,
Figure 2B) in NT2/D1 cells.
Enhancer-Associated H3R2me2a Promotes the
Deposition of H3K4me1/H3K27ac and the
Transcriptional Activation of Corresponding Genes
To investigate the role of enhancer-associated H3R2me2a bind-
ing sites, we plotted these peaks according to their affiliation to
cluster I, II, and III in NT2/D1 CT and KO cells and compared
them to the ChIP-seq profiles of H3K4me3, H3K4me1, and
H3K27ac (Figure 4A). As mentioned above, enhancer-associ-
ated H3R2me2a peaksmainly belong to cluster III (i.e., increased
peak intensity in plus ATRA) and generally show very low occu-
pancy of H3K4me3. Strikingly, deposition of H3K4me1 and
H3K27ac resembled the occurrence of H3R2me2a at cluster
III genes. The occupancy of both enhancer marks clearly
augmented upon differentiation of NT2/D1 CT cells (comparing
CTminus/plus ATRA, Figures 4A and 4B). This ATRA-induced in-
crease was significantly diminished upon deletion of PRMT6
(comparing CT and KO, both plus ATRA), suggesting that the dif-
ferentiation-associated depositions of H3R2me2a and the two
enhancer marks are connected. This assumption was supported
by the facts that PRMT6 knockout had a very moderate impact
on the H3K4me1/H3K27ac occupancy in undifferentiated cells
(comparing CT and KO, both minus ATRA), and further that the
ATRA-induced increased deposition of enhancer marks was
only marginally detectable in KO cells (comparing KO minus/
plus ATRA, Figures 4A and 4B). Moreover, we observed a strong
positive correlation between the enrichment levels of H3R2me2a
and both enhancer marks in differentiating CT cells (Figures S6A
and S6B). Collectively, our findings point to an H3R2me2a-
dependent deposition mechanism of these enhancer histone
marks.
The H3K4 mono-methyltransferase KMT2D contains several
PHD fingers, of which PHD4-6 are well-known reader domains
of histone H4 (Dhar et al., 2012). We investigated here whether
KMT2D also binds to the histone H3 tail and whether this binding
is influenced by H3R2me2a. Therefore, we performed peptide
pull-down assays using either recombinant GST-KMT2Dpurified
from bacteria or Flag-KMT2D overexpressed in cell lysates. By
means of wild-type and mutant KMT2D proteins, we found that
PHD4-6 of KMT2D, in particular PHD6, possess binding prefer-
ences for H3R2me1 and H3R2me2a peptides, but not for
H3R2me0, H3R2me2s, or H3R17me2a (Figures 4C, S6C, and
S6D). In agreement with these findings, ChIP-seq analysis of
KMT2D in NT2/D1 CT and KO cells showed a co-occurrence
of H3R2me2a and KMT2D (Figures 4A, 4B, and S6E–S6I).
Furthermore, we detected a positive correlation of H3R2me2a
and KMT2D enrichment levels at the chromatin and, importantly,
a dependence of KMT2D binding on H3R2me2a deposition (Fig-
ures S6G–S6I). Our data suggest that PRMT6 facilitates the
deposition of H3K4me1 potentially in a direct manner by
enhancing chromatin recruitment of the KMT2D complex, which
has been reported to promote p300-dependent H3K27 acetyla-
tion (Wang et al., 2016, 2017).Cell Reports 24, 3339–3352, September 18, 2018 3343
Figure 3. Negative Influence of Promoter-Associated H3R2me2a on H3K4me3 Deposition and Transcriptional Activity of Target Genes
(A) Boxplot analysis presents the normalized H3K4me3 tag counts for upregulated (red boxes) and downregulated genes (green boxes) in NT2/D1 CT and KO
cells. ***p% 0.001; n.s.: not significant using Welch’s t test.
(B) Genome browser views of the H3R2me2a and H3K4me3 ChIP-seq datasets generated in NT2/D1 CT and KO cells are shown for the indicated gene loci (left
panels). H3K4me3 signal differences between NT2/D1 KO and CT are illustrated in a separate track (KO-CT). Positions of amplicons generated by qPCR are
depicted as black boxes above the top browser tracks. Data range is indicated in brackets. ChIP-qPCR assays were performed in NT2/D1 CT and KO cells using
control antibodies (IgG) or a-H3K4me3 and primers encompassing the H3R2me2a peaks of the different loci. Recruitment is displayed in percent input of
chromatin; mean ± SD of triplicates (right panels).
(C) Total RNA of NT2/D1 CT and KO cells was analyzed by RT-qPCR for transcript levels of the indicated genes (studied in B). Values were normalized to
UBIQUITIN (UBC) expression and presented relative to NT2/D1 CT cells; mean ± SD of triplicates.
(D) ChIP-qPCR assays were performed in NT2/D1 CT and KO cells using control antibodies (IgG) or a-KMT2A and primers encompassing the H3R2me2a peaks
(spec, specific region) of the different loci (studied in B) as well as a control region for LARS (=control; 18 kb downstream of TSS in exon 6). Recruitment is
displayed in percent input of chromatin; mean ± SD of triplicates.
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Figure 4. Promotion of H3K4me1 and H3K27ac Deposition by Enhancer-Associated H3R2me2a
(A) Heatmap presents the 4,583 enhancer-associated H3R2me2a binding sites in NT2/D1 CT cells minus/plus ATRA (as well as in KO cells) according to their
affiliation to the three clusters and in comparison to H3K4me3, H3K4me1, H3K27ac, and KMT2D ChIP-seq profiles.
(B) Boxplot analysis illustrates the normalized tag counts ±2 kb centering H3R2me2a peaks for all samples of cluster III in (A). *p% 0.05; ***p% 0.001; n.s., not
significant using Welch’s t test.
(C) Indicated histone H3 peptides (aa 1–8) were covalently coupled to Sulfolink beads and incubated with bacterially expressed and purified GST-KMT2D PHD4-6
protein. Pull-down reactions and 5% input of GST-KMT2D deletion protein were resolved by SDS-PAGE and analyzed by a-GST western blot. Silver staining of
the H3 peptides served as loading control.
(D) Boxplot analysis illustrates the transcriptional strength of the 137 deregulated genes upon PRMT6 knockout, which associate with H3R2me2a enhancer
marks, in NT2/D1 CT and KO cells minus/plus ATRA. ***p% 0.001 using Welch’s t test.
(E) Heatmap visualizes expression changes of genes from (D) upon ATRA treatment of NT2/D1 CT as well as KO cells.Consequently, we next asked whether deposition of
H3R2me2a at enhancer sites affects the transcription of associ-
ated genes. Therefore, we analyzed the transcript levels of the
137 genes, which were found deregulated upon PRMT6 deletionin plus-ATRA condition and associate with H3R2me2a in their
enhancer region (Figure S5B). The majority of these H3R2me2
target genes, which belong to cluster III, showed an increased
expression upon ATRA-induced differentiation in CT cellsCell Reports 24, 3339–3352, September 18, 2018 3345
Figure 5. Transcriptional Activation Due to Enhancer-Associated H3R2me2a
(A) Genome browser views are shown for the indicated cluster III genes of H3R2me2a, H3K4me1, and H3K27ac ChIP-seq datasets generated in NT2/D1 CT and
KO cellsminus/plus ATRA (left panels). Data range is indicated in brackets. ChIP-qPCR assayswere performed in NT2/D1 cells using the indicated antibodies and
primers encompassing the histone modification peaks of the different loci. Recruitment is displayed in percent input of chromatin; mean ± SD of triplicates (right
panels).
(B) ChIP-qPCR assays, as described in (A), were performed for KMT2D in NT2/D1 cells. The color code of the four conditions is displayed in (A).
(C) Transcript levels of the indicated cluster III genes (studied in A) were analyzed by RT-qPCR in NT2/D1 CT and KO cells minus/plus ATRA. The color code of the
four conditions is displayed in (A). Values were normalized toUBIQUITIN (UBC) expression and presented relative to NT2/D1 CT cells minus ATRA; mean ± SD of
triplicates.(comparing CT minus/plus ATRA, Figure 4D). In contrast, in
KO cells, ATRA treatment did not result in any significant in-
crease in transcript levels of these genes (comparing KO
minus/plus ATRA, Figure 4D). Importantly, comparing CT and
KO in plus ATRA, PRMT6 knockout led to a loss of the
differentiation-dependent transcriptional activation (Figure 4D).
Besides, a heatmap of these transcriptional changes revealed
that the very same genes, which were activated upon
ATRA treatment in CT cells, lost their transcriptional response
upon PRMT6 knockout (Figure 4E). Independent ChIP-
qPCR and RT-qPCR assays of candidate cluster III genes,
such as VTCN1, RP11-834C11.4, and CRABP1, validated the3346 Cell Reports 24, 3339–3352, September 18, 2018effects of PRMT6 deletion on H3K4me1/H3K27ac deposition,
KMT2D recruitment, as well as transcriptional output (Figures
5A–5C and S7A). Moreover, re-expression of PRMT6 in
NT2/D1 KO cells (Figure S2A) resulted in a rescue of the
ATRA-induced H3K27ac deposition and differentiation-depen-
dent transcriptional activation of associated genes (Figure
S7B). Hence, our findings reveal that enhancer-associated
H3R2me2a is predominantly deposited in a differentiation-
dependent manner in NT2/D1 cells. There, it possibly promotes
the deposition of H3K4me1 and H3K27ac, by recruitment of
KMT2D, and thus enables transcriptional activation upon neural
differentiation.
Figure 6. Impact of PRMT6 on Neural Differentiation and Proliferation In Vitro and In Vivo
(A) Transcript levels of OCT4 and NANOG were analyzed by RT-qPCR in NT2/D1 CT versus KO cells minus/plus ATRA. Values were normalized to UBIQUITIN
(UBC) expression and presented relative to NT2/D1 CT cells minus ATRA; mean ± SD of triplicates.
(B and C) The fraction of SSEA3-positive and SSEA3-negative cells was measured by flow cytometry of NT2/D1 CT and KO cells in minus- and plus-ATRA
conditions. HeLa cells (black dotted line) served as negative control to define gates of SSEA3-positive and SSEA3-negative cells (black bars). (B) shows an
(legend continued on next page)
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PRMT6 Influences the Differentiation and Proliferation
Capacity of NT2/D1 Cells and of Neural Precursor Cells
in the Developing Mouse Cortex
Given the enhanced expression of pluripotency-associated
genes in NT2/D1 KO cells before and after ATRA treatment, as
illustrated forOCT4 andNANOG (Figure 6A), we raised the ques-
tion whether PRMT6 influences the differentiation capacity of
NT2/D1 cells. Undifferentiated NT2/D1 cells express the cell sur-
face marker SSEA3, which indicates their stem cell-like state
(Houldsworth et al., 2002). Using flow cytometry, we found that
a higher percentage of NT2/D1 KO cells is SSEA3-positive and
thusmore pluripotent in the undifferentiated condition compared
to CT cells (Figures 6B and 6C). Upon ATRA treatment, this dif-
ference was even more pronounced, suggesting that PRMT6
knockout leads to reduced neural differentiation. Additionally,
undifferentiated NT2/D1 KO cells displayed a prolonged G1
phase and diminished proliferation rate (S phase) compared to
CT cells, as measured by flow cytometry using propidium iodide
staining (Figure S8A). These proliferation and differentiation de-
fects of KO cells were rescued upon re-expression of PRMT6,
which restored a higher number of cells in S phase, a reduced
percentage of pluripotent (SSEA3-positive) cells in the minus-
ATRA condition and an increased fraction of differentiating
(SSEA3-negative) cells upon ATRA treatment (Figures 6D, S8B,
and S8C). To further address whether the catalytic activity of
PRMT6 is responsible for the neural differentiation phenotype
of KO cells, we treated NT2/D1 CT cells with MS049, a potent
PRMT6 inhibitor (Shen et al., 2016). This treatment resulted in
a global reduction of arginine methylated proteins and a reduced
genomic occupancy of H3R2me2a (Figures S8D–S8F). Interest-
ingly, MS049 treatment phenocopied the defects on pluripo-
tency and differentiation caused by PRMT6 knockout, indicating
that these PRMT6-mediated functions require its catalytic activ-
ity (Figures 6E and S8G).
Since differentiating NT2/D1 cells resemble Pax6-positive
neural stem cells of the developing fetal CNS (Houldsworth
et al., 2002), we investigated whether Prmt6 also influences neu-
ral differentiation in vivo in mice. First, we analyzed the protein
expression of Prmt6 in fetal and adult murine brain tissue. In
agreement with previous studies, we found Prmt6 to be highly
expressed in the developing mouse brain (McKee et al., 2005)exemplary experiment. (C) displays the quantification of SSEA3-positive (SSEA
Welch’s t test.
(D) NT2/D1 KO_Flag-PRMT6 cells were cultured in the absence or presence of PR
(last 3 days). The fraction of SSEA3-positive and SSEA3-negative cells wasmeasu
to define gates of SSEA3-positive and SSEA3-negative cells (black bars). An exem
shown in Figure S8C.
(E) The fraction of SSEA3-positive and SSEA3-negative NT2/D1 CT cells either un
by flow cytometry. HeLa cells (black dotted line) served as negative control to
exemplary experiment is shown. Quantification of four independent experiments
(F) Cryosections of the developing murine cerebral cortex of Prmt6+/ (HET) or Prm
green) as a neural progenitor cell marker, which recognizes the abundant numb
opmental stage, for Ki67 (in green) as a marker of the proliferating progenitors (pr
(PI) (in red) as a nuclear/DNA stain. The VZ (stained by Pax6) and the VZ/SVZ (sta
account for cell counting (G) and layer width quantification (H). The ventricles (V)
(G and H) For quantification of progenitor cell numbers as well as VZ and VZ/SVZ l
respectively, of a standardized area were determined in a blinded way from five t
numbers (G) and layer width (H) of WT/HET versus KO condition are depicted as
3348 Cell Reports 24, 3339–3352, September 18, 2018as well as in different regions of the adult mouse brain (Fig-
ure S8H). Given that Pax6-positive as well as proliferating
(Ki67-positive) neural progenitor cells are highly abundant in
the mouse cerebral cortex of embryonic day 12.5 (E12.5), we
quantified the progenitor numbers of this developmental stage
in wild-type (WT) and heterozygous (HET) versus Prmt6 KO
mice (Neault et al., 2012). Thereby, we identified that the
numbers of Pax6-positive and Ki67-positive progenitors,
respectively, as well as the layer widths of the ventricular zone
(VZ) and subventricular zone (SVZ) are reduced in the cerebral
cortex of Prmt6 KO embryos compared toWT and HET embryos
(Figures 6F–6H). At later developmental stages and in the adult
murine brain, we did not find significant differences in the num-
ber of neurons and in the morphology of the brain between
WT/HET and KO animals (data not shown). Our observations
are consistent with the inconspicuous phenotype of Prmt6 KO
mice (Neault et al., 2012). We hypothesize that the important
in vivo functions of Prmt6 are partially compensated in the KO
mouse model by other Prmt members. Hence, these findings
show that PRMT6-deficient neural cells display a very stable
stem cell-like state and a perturbation of their proliferation and
differentiation capacity in an in vitro cell model as well as in vivo.
Additional mechanisms involving non-catalytic functions and
other substrates of PRMT6 could contribute to the here-
described effects of PRMT6 knockout.
In summary, our data identify PRMT6 as a regulator of neural
differentiation that seems to influence the transcription program
of neural precursors, as exemplified here for NT2/D1 cells, at
least in two ways: promoter-associated H3R2me2a diminishes
the transcription of critical pluripotency genes, whereas
enhancer-associated H3R2me2a promotes transcriptional acti-
vation of differentiation-associated genes.
DISCUSSION
To investigate the gene-regulatory functions of PRMT6 and its
major histone mark H3R2me2a in an unbiased and genome-
wide manner, we established CRISPR/Cas9-mediated deletion
of PRMT6 in the human embryonal carcinoma cell line NT2/D1.
In this well-established cell model, PRMT6 has previously been
shown to regulate the ATRA-induced transcription program of3+) cells of three independent experiments. The p values are indicated using
MT6 re-expression (minus/plus doxycycline for 6 days) and minus/plus ATRA
red by flow cytometry. HeLa cells (black dotted line) served as negative control
plary experiment is shown. Quantification of four independent experiments is
treated or treated for 3 days with ATRA, MS049 (16 mM), or both was measured
define gates of SSEA3-positive and SSEA3-negative cells (black bars). An
is shown in Figure S8G.
t6/ (KO) embryos (E12.5) were stained by immunofluorescence for Pax6 (in
er of apical radial glial cells of the murine ventricular zone (VZ) at this devel-
edominantly in the VZ and SVZ [subventricular zone]) and for propidium iodide
ined by Ki67) are indicated between the white dotted lines and were taken into
are marked.
ayer width in the murine cerebral cortex of E12.5, Pax6- and Ki67-positive cells,
o six Prmt6+/+ (WT) or Prmt6+/ (HET) and six Prmt6/ (KO) embryos. The cell
boxplot. ***p% 0.001 using Welch’s t test.
neural differentiation (Hyllus et al., 2007; Stein et al., 2016).
Furthermore, PRMT6 is highly expressed in the developing
mouse brain and has been suggested to influence the differenti-
ation of embryonic stem cells (Lee et al., 2012; McKee et al.,
2005). Recent studies disclosed a function of PRMT6 in the
regulation of cocaine addiction in adult brain (Damez-Werno
et al., 2016). Hence, using control and PRMT6 knockout NT2/
D1 clones, we analyzed the impact of PRMT6-dependent
H3R2me2a in pluripotency and neural differentiation. Here,
PRMT6-deficient NT2/D1 cells displayed a slower growth rate
compared to CT cells, in agreement with a higher number of cells
in G1 phase and increased expression levels of cell cycle inhib-
itors such as CDKN1A and CDKN2B (data not shown). Addition-
ally, PRMT6-deficient cells expressed more SSEA3 at their
surface than their control counterparts, suggesting that, in
absence of PRMT6, cells tend to retain their pluripotency state
even after ATRA-induced differentiation. These findings conform
with the observed cell cycle defects, since stem cells often show
a low proliferation rate and a bias to quiescence (Glauche et al.,
2009). Similarly, we observed reduced numbers of Pax6-positive
and proliferating neural progenitors, respectively, during murine
neurogenesis in vivo. Altogether, our data reveal that PRMT6
loss promotes the pluripotency state and perturbs the prolifera-
tion as well as differentiation capacity of NT2/D1 cells and neural
precursor cells in the developing mouse brain, indicating that
PRMT6 contributes to these key biological processes.
ChIP-seq profiling using anti-H3R2me2a antibodies revealed
that the H3R2me2a peaks detected in NT2/D1 cells were
PRMT6-dependent, as shown by the strongly reduced or lost
H3R2me2a enrichment in PRMT6 knockout cells. Although
PRMT6 and PRMT4 have been found to possess partially over-
lapping substrate specificity in certain cell types, such as mouse
embryonic fibroblasts, PRMT6 seems to be the predominant
methyltransferase for H3R2 in NT2/D1 cells (Torres-Padilla
et al., 2007). In previous studies, we and others found that
H3R2me2a mainly contributes to gene repression and occurs
at silent genes (Guccione et al., 2007; Hyllus et al., 2007; Iberg
et al., 2008). Intriguingly, we identified here that H3R2me2a is pri-
marily deposited at active genes in NT2/D1 cells, both at pro-
moter and enhancer sites. This apparent discrepancy is likely
due to the fact that the hitherto-existing knowledgewas predom-
inantly obtained from analyses of individual genes and lacked
unbiased genome-wide approaches to map the PRMT6-depen-
dent H3R2me2a deposition as well as its cross talk with neigh-
boring histone marks. Our attempts to also identify the PRMT6
binding sites in NT2/D1 cells by ChIP-seq unfortunately failed.
All currently commercially available and in-house-generated
PRMT6 antibodies did not efficiently immunoprecipitate
PRMT6 from chromatin. Based on these observations and the
fact that our in-house-generated antibodies showed specific
though weak enrichment of chromatin-bound PRMT6 (Hyllus
et al., 2007; Stein et al., 2012, 2016), we conclude that PRMT6
is a very dynamic nuclear protein, which transiently interacts
with chromatin and therefore might escape detection, even
when using double-cross-linking ChIP strategies.
Our analysis of the PRMT6-dependent transcriptome in NT2/
D1 cells showed that 25% of deregulated genes associate with
H3R2me2a binding sites in their proximity and are regarded asdirect targets of H3R2me2a. Strikingly, the majority of these
genes were downregulated, indicating a predominant transcrip-
tional activating function of the mark. These findings are in
agreement with studies reporting an activating role of PRMT6,
e.g., in nuclear hormone receptor-dependent transcription (Har-
rison et al., 2010). The remaining genes, which are not marked by
H3R2me2a, but show an altered transcriptional output upon
PRMT6 deletion, are likely regulated by different mechanisms.
This notion is in agreement with the findings that PRMT6 meth-
ylates several other substrates at the chromatin, for example,
histone H3 at other arginines (H3R42), other histones (H2A,
H4), and transcription factors (Casadio et al., 2013; Herglotz
et al., 2013; Hyllus et al., 2007; Waldmann et al., 2011). Addition-
ally, non-catalytic functions of PRMT6 and indirect mecha-
nisms might account for transcriptional deregulation of these
H3R2me2a-independent target genes. For example, CDKN1A,
which has been shown to be a direct target of H3R2me2a in
several human cell lines (Kleinschmidt et al., 2012; Phalke
et al., 2012; Stein et al., 2012), does not show any enrichment
of the mark in its promoter or enhancer region in NT2/D1 cells,
despite being upregulated in the absence of PRMT6 (data not
shown). Interestingly, the transcription factor MITF, which has
been reported to activate CDKN1A expression (Carreira et al.,
2005), is a downregulated and direct H3R2me2a target gene in
NT2/D1 cells and hence might be responsible for the enhanced
CDKN1A transcript levels in PRMT6 knockout cells.
Our analysis of the gene-regulatory role of H3R2me2a at pro-
moter and enhancer sites uncovered further unexpected in-
sights. This mark seems to execute opposing transcriptional
effects depending on its genomic location: repressive functions
at promoters and activating functions at enhancers (Figure 7).
Promoter-bound H3R2me2a co-localizes with high H3K4me3
occupancy and antagonizes the deposition of this well-known
active promoter mark, likely by interfering with the recruitment
of KMT2A. This results in a diminished transcriptional activity
of target genes. Our findings extend the understanding on the
previously reported repressive nature of H3R2me2a, since this
rather occurs at active genes than at silent gene loci, causing a
restraint of their transcriptional output (Guccione et al., 2007;
Hyllus et al., 2007; Iberg et al., 2008). PRMT6, potentially via
H3R2me2a deposition at gene promoters, leads to fine-tuning
of the transcriptional program in NT2/D1 cells and impedes
unauthorized high expression of pluripotency genes as well as
differentiation-associated genes (Figure 7A). In contrast, non-
promoter H3R2me2a peaks co-localize with active enhancer
marks, such as H3K4me1 and H3K27ac. Here, H3R2me2amight
positively influence the deposition of these two enhancer marks,
possibly by recruitment of KMT2D (subsequently p300), and
thereby contributes to transcriptional activation of the associ-
ated genes (Figure 7B). At both locations, promoter as well as
enhancer sites, H3R2me2a seems to modulate the deposition
of adjacent histone marks, in agreement with the concept
that arginine methylation exerts its regulatory activity by facili-
tating or diminishing protein-protein interactions. Whether
H3R2me2a is sufficient and thereby decisive for regulating the
chromatin recruitment of KMT2A and KMT2D requires further in-
vestigations in the future. Collectively, we conclude that PRMT6,
likely via its catalytic activity and H3R2me2a, regulates theCell Reports 24, 3339–3352, September 18, 2018 3349
Figure 7. Model for the PRMT6-Dependent Deposition and Function of H3R2me2a at Promoter and Enhancer Sites
(A) Promoter-deposited H3R2me2a peaks (red circles) occur in proximity to the TSS of target genes, which are concomitantly marked with high H3K4me3
occupancy (green circles). These H3R2me2a binding sites associate with genes of medium to high expression levels. Here, PRMT6, potentially via H3R2me2a,
diminishes the transcriptional output of target genes by counteracting KMT2A/H3K4me3 (upper panel). Deletion of PRMT6 and concomitant loss of H3R2me2a
lead to increased binding of KMT2A as well as increased occupancy of H3K4me3 (as illustrated by the larger green circles) and unauthorized high expression of
pluripotency and differentiation-associated genes (lower panel).
(B) Enhancer-deposited H3R2me2a (red circles) co-localizes with the active enhancer marks H3K4me1 and H3K27ac (purple and green circles, respectively).
Here, PRMT6, potentially via H3R2me2a, enhances the transcriptional output of target genes by positively influencing the deposition of H3K4me1/H3K27ac,
possibly through recruitment of KMT2D and subsequently p300 (upper panel). Deletion of PRMT6 and concomitant loss of H3R2me2a coincide with decreased
binding of KMT2D as well as occupancy of H3K4me1/H3K27ac (as illustrated by the smaller circles) and impaired differentiation-dependent transcriptional
activation of these important target genes (lower panel).transcriptional output of genes relevant for neural differentiation
through opposing effects on promoter and enhancer activities
(Figure 7).
EXPERIMENTAL PROCEDURES
Cell Lines and Reagents
NT2/D1, U2OS, HeLa, and HEK293T cells were maintained in DMEM supple-
mented with 10% fetal calf serum (FCS) (Gibco-BRL) and 1% penicillin/strep-
tomycin at 37C and 5% CO2. Neural differentiation of NT2/D1 cells was
induced with 1 mM ATRA (Sigma) according to the protocol of Andrews
(1984). MS049 hydrochloride was purchased from Sigma (SML15530).
Detailed information on antibodies and plasmids is supplied in Supplemental
Experimental Procedures.
Production of Lentiviral Particles and Infection of Cells
For CRISPR/Cas9-mediated deletion of PRMT6 in NT2/D1 and U2OS cell as
well as doxycycline-inducible expression of PRMT6 in NT2/D1 KO cells,
HEK293T cells were transfected with packaging plasmids and lentiviral
expression plasmids. Subsequently, lentiviral particles were used for cell
infection as described in Supplemental Experimental Procedures.
Synthetic Histone Peptides
Unmodified and modified N-terminal histone peptides followed by a C-termi-
nal cysteine residue or biotin moiety were obtained from Peptide Specialty
Laboratories (Heidelberg, Germany). Modified peptides were synthesized by
using either monomethylated, asymmetrically dimethylated, symmetrically di-
methylated arginine, or mono-, di-, trimethylated lysine. Dot blot analysis and
peptide pull-downs were performed as described in Supplemental Experi-
mental Procedures.3350 Cell Reports 24, 3339–3352, September 18, 2018Flow Cytometry
For quantification of the cell cycle distribution as well as pluripotency marker
analysis, flow cytometry was used as described in Supplemental Experimental
Procedures.
Animals
Constitutive Prmt6 / (KO) mice were provided by the laboratory of Ste-
phane Richards (Neault et al., 2012). For generation ofPrmt6/ (KO),Prmt6+/
(HET), andPrmt6+/+ (WT) embryos of E12.5, pregnant female mice (Prmt6HET)
were sacrificed by cervical dislocation, and embryos were decapitated. Killing
of mice for tissue preparation was as approved by the animal protection
commissioner of the University of Marburg. Tissue preparation and analysis
are described in detail in Supplemental Experimental Procedures.
RNA Isolation, RT-qPCR, and RNA-Seq
RT-qPCR and RNA-seq were performed as described in Supplemental Exper-
imental Procedures.
ChIP-qPCR and ChIP-Seq
For immunoprecipitation of histone marks, cells were cross-linked with 1%
formaldehyde, whereas for immunoprecipitation of histone modifiers addition-
ally disuccinimidyl glutarate (DSG) was used. ChIP experiments and detailed
settings of genomic analyses are described in Supplemental Experimental
Procedures.
Statistical Analysis
All experiments were performed at least three times (biological replicates).
Reproducible and representative datasets are shown. Corresponding statisti-
cal tests are mentioned in the figure legends. Error bars represent mean ± SD
of triplicate measurements.
DATA AND SOFTWARE AVAILABILITY
The accession number for the ChIP-seq and RNA-seq data reported in this pa-
per is GEO: GSE107612.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and eight figures and can be found with this article online at https://doi.org/
10.1016/j.celrep.2018.08.052.
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